Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601003 · ClinicalTrials.gov registry record · Phase 2
Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
A Phase 2 study, sponsored by Giselle Sholler.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00601003 is a Phase 2 study that has completed, run by Giselle Sholler. The registered enrollment target is 112 participants.
The verdict
NCT00601003, a Phase 2 study, has completed, sponsored by Giselle Sholler.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
Interventions
- DRUG Cyclophosphamide
- DRUG Topotecan
- DRUG Nifurtimox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2008-01-14 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601003
The ClinicalTrials.gov registry entry for NCT00601003 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Giselle Sholler, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT00601003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601003 about?
NCT00601003 is a clinical study titled "Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma". The purpose of this study is to determine whether nifurtimox in combination with cyclophosphamide and topotecan are effective in the treatment of relapsed or refractory neuroblastoma and medulloblastoma.
What is the current status of trial NCT00601003?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2008-01-14. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT00601003?
The interventions under investigation include: Cyclophosphamide (DRUG), Topotecan (DRUG), Nifurtimox (DRUG).
Who is sponsoring clinical trial NCT00601003?
This trial is sponsored by Giselle Sholler, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.